Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer

Kate Webber, Michael L. Friedlander

Research output: Contribution to journalReview ArticleResearchpeer-review

24 Citations (Scopus)

Abstract

Chemotherapy plays a key role in the management of women with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Platinum- and taxane-based regimens are the standard of care for adjuvant treatment in early-stage EOC and first-line therapy for advanced stage disease. Efforts to define the optimal scheduling, timing and route of administration are ongoing. The majority of women with EOC will develop recurrent disease, and treatment options for these women are depend on the time that has elapsed from first-line therapy. Platinum-based doublet chemotherapy is preferred for women with platinum-sensitive recurrent cancer. In platinum-resistant relapsed EOC, options are much more limited, and careful consideration of symptoms, performance status, anticipated toxicity and quality of life is essential when recommending chemotherapy for these women.

Original languageEnglish
Pages (from-to)126-138
Number of pages13
JournalBest Practice & Research: Clinical Obstetrics & Gynaecology
Volume41
DOIs
Publication statusPublished - 1 May 2017
Externally publishedYes

Keywords

  • chemotherapy
  • epithelial ovarian cancer

Cite this